|
|
Post by lennymnkd on Sept 16, 2018 17:29:27 GMT -5
Should my hopes be dashed for a migraine drug for the technosphere platform, Both Teva ( AJOVY) and Eli Lilly’s (GALCANEZUMAP ) have migraine drugs both with an injection “every few months “ cluster migraines ... doesn’t seem to be an advantage without having to be administered on a more frequent basis /chronic / for technosphere..  ?. |
|
|
|
Post by Omega on Sept 16, 2018 17:41:01 GMT -5
How perfect would this be? UTHR says "We are putting 3 drugs on Technosphere"! Then hands Mannkind 120 Million dollars plus royalties. 😁😉🤑 That would be perfect........if accepted in the marketplace. We have to remember that just because Technosphere is used with other compounds it doesn't mean it will be accepted in the marketplace. If it is successful then we will realize the dream of Al Mann. I want to see revenue. Show me the revenue! Actually we get the initial 40m dollars from UT per new drug, long before anyone will know how successful or not it will be once on the market. |
|
|
|
Post by sportsrancho on Sept 16, 2018 19:45:11 GMT -5
Should my hopes be dashed for a migraine drug for the technosphere platform, Both Teva ( AJOVY) and Eli Lilly’s (GALCANEZUMAP ) have migraine drugs both with an injection “every few months “ cluster migraines ... doesn’t seem to be an advantage without having to be administered on a more frequent basis /chronic / for technosphere.. ?. I hope for that also, my girlfriend used to get horrible migraines but if she caught them right away when she could feel them starting they didn’t materialize. If she didn’t she would just have to lay on the floor and shut her eyes and endure the pain because the meds she would take took so long to reach her. So one inhalation might be all it would take in some cases. |
|
|
|
Post by falconquest on Sept 17, 2018 6:20:59 GMT -5
That would be perfect........if accepted in the marketplace. We have to remember that just because Technosphere is used with other compounds it doesn't mean it will be accepted in the marketplace. If it is successful then we will realize the dream of Al Mann. I want to see revenue. Show me the revenue! Actually we get the initial 40m dollars from UT per new drug, long before anyone will know how successful or not it will be once on the market. Unfortunately that is not a sustainable strategy. This company (or by fiat through it's partnerships) needs to sell product and generate revenue. If the product doesn't sell then future deals will not happen. |
|
|
|
Post by patten1962 on Sept 18, 2018 6:20:40 GMT -5
Perhaps Mike just made an error and meant end of October which if the 23rd is the end of the month, and not September. Totally possible but not what he said. He said "Investor Call" not Earnings call. Today is only the 15th. My hope is UTHR has something big to say, then Mike can talk about it at Cantor! Got that idea from Sports! 😉 ☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆ September 18, 2018 Back United Therapeutics Corporation To Host Science Day 2018 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will host Science Day 2018 in New York City on Monday, September 24th, beginning at approximately 10:00 A.M. Eastern Time and ending at approximately 4:00 P.M. Eastern Time. Science Day 2018 will include a series of science-centric presentations by clinicians, industry leaders as well as senior leadership of United Therapeutics taking a deep dive into our balanced, value-creating research and development pipeline. Attendance in-person is by invitation only; however, the event will also be webcast live and can be accessed on the United Therapeutics website at www.unither.com under the "Investors" tab in the "Events and Presentations" section. An archived, recorded version of the presentation will be available approximately twenty-four hours after the event ends and can be accessed at the same location for 90 days. [uthr-g] About United Therapeutics United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. Cision View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-host-science-day-2018-300714053.html SOURCE United Therapeutics Corporation For Further Information Contact: James Edgemond at (301) 608-9292, Email: jedgemond@unither.com |
|
|
|
Post by sportsrancho on Sept 18, 2018 6:24:28 GMT -5
|
|
|
|
Post by patten1962 on Sept 18, 2018 6:29:04 GMT -5
I knew I heard Mike C correctly! 😁 |
|
|
|
Post by patten1962 on Sept 18, 2018 7:28:05 GMT -5
So now the big question:
Will this announcement drive Mannkind Stock Price up because of the anticipated news we all hope we might get?
I am not say any news is coming I am just hoping!
😁
|
|
|
|
Post by mango on Sept 20, 2018 14:47:48 GMT -5
Totally possible but not what he said. He said "Investor Call" not Earnings call. Today is only the 15th. My hope is UTHR has something big to say, then Mike can talk about it at Cantor! Got that idea from Sports! 😉 ☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆ September 18, 2018 Back United Therapeutics Corporation To Host Science Day 2018 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will host Science Day 2018 in New York City on Monday, September 24th, beginning at approximately 10:00 A.M. Eastern Time and ending at approximately 4:00 P.M. Eastern Time. Science Day 2018 will include a series of science-centric presentations by clinicians, industry leaders as well as senior leadership of United Therapeutics taking a deep dive into our balanced, value-creating research and development pipeline. Attendance in-person is by invitation only; however, the event will also be webcast live and can be accessed on the United Therapeutics website at www.unither.com under the "Investors" tab in the "Events and Presentations" section. An archived, recorded version of the presentation will be available approximately twenty-four hours after the event ends and can be accessed at the same location for 90 days. [uthr-g] About United Therapeutics United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. Cision View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-host-science-day-2018-300714053.html SOURCE United Therapeutics Corporation For Further Information Contact: James Edgemond at (301) 608-9292, Email: jedgemond@unither.com Looks like a platform for disclosure of potential future UT/MannKind Technosphere applications. |
|
|
|
Post by lakers on Sept 20, 2018 20:53:23 GMT -5
You thought UTHR PAH Deal was big. The Following will numb you - Inhaled Humira for Rheumatoid Arthritis, instant relief. It was bandied about when Al was alive. www.google.com/amp/s/www.yahoo.com/amphtml/finance/news/abbvie-faces-california-insurance-department-150403837.htmlHumira is key driver of AbbVie’s revenues, accounting for more than 60% of its total sales. Currently approved for 13 indications, Humira sales have increased consistently, backed by robust demand trends. Humira recorded sales of almost $10 billion in the first half of 2018.Several companies including Amgen AMGN/Allergan AGN, Mylan MYL, Coherus, Novartis’ Sandoz, Pfizer and Samsung Bioepis are working on biosimilar versions of Humira. The entry of biosimilars will have a huge impact on AbbVie’s financials. Amgen, Mylan and Samsung Bioepis/Biogen’s Humira biosimilars are expected to be launched in the United States in 2023 while in the EU, Amgen and Biogen’s biosimilars are expected to be launched in October this year.The latest lawsuit adds to AbbVie’s Humira related woes. July 18, 2018 AbbVie, Inc. (ABBV - Free Report) has signed a non-exclusive licensing deal with Mylan (MYL - Free Report) regarding the latter’s proposed biosimilar version of AbbVie’s blockbuster arthritis drug, Humira, in the United States. Per the agreement, Mylan will have a license to launch its biosimilar Humira in the United States and in various other countries, excluding Europe, on Jul 31, 2023.Per the terms of the settlement, Mylan will pay royalties to AbbVie once its cheaper version is launched. AbbVie will make no payments to Mylan.AbbVie has similar licensing deals with Amgen, Inc. (AMGN - Free Report) and Samsung Bioepis. While Amgen can launch Amjevita, its biosimilar version of Humira in the United States on Jan 31, 2023, Samsung Bioepiscan launch Imraldi, its biosimilar version on Jun 30, 2023. While Amgen and Samsung Bioepis’biosimilar versions are already approved by the FDA, that of Mylan is yet to gain FDA approval.AbbVie made it clear that Mylan's U.S. license will not be accelerated by Amgen's or Samsung Bioepis' biosimilar launch. In most countries of Europe, Samsung Bioepis’ partner Biogen (BIIB - Free Report) and Amgen have license to launch their biosimilar versions from Oct 16 this year.Humira is the key driver of AbbVie’s revenues, accounting for around 65% of its total sales. Currently approved for 13 indications, Humira sales have increased consistently — 11.7% in 2015, 16.1% in 2016 and 14.6% in 2017 — backed by robust demand trends. The product continues to see strong growth in the dermatology and gastroenterology markets. The company expects Humira sales to approach $21 billion in 2020.Other than, Amgen, Mylan and Samsung Bioepis, Coherus BioSciences, Boehringer Ingelheim, Novartis’ Sandoz and Pfizerare also looking to get approval for a biosimilar version of Humira. In May, June and July, the Patent Trial and Appeal Board (PTAB) ruled against AbbVie on five inter parties review (IPR) challenge filed by Coherus and Boehringer Ingelheim, invalidating three AbbVie patents for Humira. AbbVie has appealed the decision. The entry of biosimilars will have a huge impact on AbbVie’s financials.However, AbbVie has successfully struck licensing deals with three companies to protect its revenues from Humira. Per settlements with Amgen, Mylan and Samsung Bioepis, biosimilar entry into the United States has been delayed until2023, which gives AbbVie more time to strengthen its pipeline with products that are capable of making up for the expected sales decline when Humira biosimilars are launched.www.google.com/amp/s/www.zacks.com/amp/stock/news/312029/abbvie-settles-with-mylan-to-delay-humira-biosimilar-in-us |
|
|
|
Post by goyocafe on Sept 20, 2018 21:19:29 GMT -5
|
|
|
|
Post by lakers on Sept 20, 2018 21:50:35 GMT -5
LONDON (Reuters) 9/20/18 - Europe has approved a fifth copy of AbbVie's $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs. Mylan and Fujifilm Kyowa Kirin Biologics said on Thursday they had won a European Commission green light to market their version of the injectable medicine, known as Hulio. They intend to launch it in Europe on or after Oct. 16, when AbbVie's primary European patent on Humira expires. The large number of Humira copies reflects intense rivalry for a slice of a huge market as demand for so-called biosimilars takes off in Europe, where adoption of the cut-price products has been much faster than in the United States. Europe accounted for around $4.4 billion of Humira's global sales in the 12 months to June 30, 2018, according healthcare data consultancy IQVIA.
Amgen, Novartis's generics wing Sandoz, South Korea's Samsung Bioepis and Germany's Boehringer Ingelheim have already won approval for four other biosimilars to Humira.
Humira is used to treat a range of conditions including rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis. Its commercial success and popularity among patients means it has become a major cost for health systems across Europe, and health administrators say they will waste no time in exploiting the arrival of cheaper biosimilars to drive down bills. Because injectable biologic drugs such as Humira are made in living cells, they cannot be exact replicas of the original medicine, so regulators have come up with the notion of biosimilars - drugs that are similar enough to do the job. The conventional wisdom has been that biosimilar uptake would be slow and price discounts modest, since these products are expensive to develop and doctors may be wary about using a medicine that isn't identical to the original. But Europe's recent experience with the first wave of biosimilar antibody drugs - the biggest section of the biologic market - has upended expectations, suggesting AbbVie will face fierce competition. Still, analysts don't expect global Humira sales to fall off a cliff just yet, since there are delays in the arrival of biosimilars in the all-important U.S. market. While expiry of the Humira patent opens the door to biosimilars in Europe, such copies are not expected to launch in the United States until 2023. www.google.com/amp/s/mobile.reuters.com/article/amp/idUSKCN1M011N |
|
|
|
Post by lakers on Sept 20, 2018 22:56:57 GMT -5
Dr. Castagna joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs, and Vice President, Global Lifecycle Management. Prior to Amgen, Dr. Castagna, was Executive Director of Bristol-Myers Squibb’s Immunology franchise, where he served as co-lead to relaunch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone. Amgen, Novartis's generics wing Sandoz, both are MC’s former employers, have already won approval for Humira bio similar to be launched in the U.S in 2023.seekingalpha.com/article/4204322-mannkind-corporation-mnkd-ceo-michael-castagna-presents-rodman-and-renshaw-20th-annual-globalCompatibility with diverse API. So we do look at small molecules and peptides. I want to say we can go to 150,000 Da or pretty large molecules. We are starting to think about vaccines as well as other local drugs for local effects. |
|
|
|
Post by patten1962 on Sept 21, 2018 1:51:03 GMT -5
Dr. Castagna joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs, and Vice President, Global Lifecycle Management. Prior to Amgen, Dr. Castagna, was Executive Director of Bristol-Myers Squibb’s Immunology franchise, where he served as co-lead to relaunch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone. Amgen, Novartis's generics wing Sandoz, both are MC’s former employers, have already won approval for Humira bio similar to be launched in the U.S in 2023.seekingalpha.com/article/4204322-mannkind-corporation-mnkd-ceo-michael-castagna-presents-rodman-and-renshaw-20th-annual-globalCompatibility with diverse API. So we do look at small molecules and peptides. I want to say we can go to 150,000 Da or pretty large molecules. We are starting to think about vaccines as well as other local drugs for local effects. Great post!! |
|
|
|
Post by lakers on Sept 21, 2018 6:25:24 GMT -5
The highest price paid for a priority review is $350 million in August 2015, when United Therapeutics sold its voucher to AbbVie who can expedite Inhale Humira in less than two years to protect its $21B-a-year cash cow which is the most successful prescription drug for 13 indications including rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis, dermatology and gastroenterology markets. Read more: mnkd.proboards.com/thread/4937/meet-pahs-tacrolimus-treprostinil-inhibitor?page=2#ixzz5RjaJmYvx |
|
?.
